Author(s):
Umesh B. Kolap, Himmat Singh Chawara, Sunil T. Galatage
Email(s):
himmat.singh@nimsuniversity
DOI:
10.52711/0974-360X.2025.00810 
Address:
Umesh B. Kolap1, Himmat Singh Chawara2, Sunil T. Galatage3
1Ph. D Research Scholar, Pharmaceutical Sciences, NIMS Institute of Pharmacy, Jaipur, Rajasthan, India.
2Department of Pharmaceutical Sciences, NIMS Institute of Pharmacy, Jaipur, Rajasthan, India.
3Vasantidevi Patil Institute of Pharmacy, Kodoli, Kolhapur, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
The primary cause of mortality globally is cancer, which is defined as aberrant cell growth and proliferation. It is an incurable condition in which the person's environment interacts with the DNA to cause many alterations. There are many different therapy options for cancer; however, innovative drug delivery systems, or NDDS, are a newer kind of medicine. NDDS, which mostly consists of liposomes, niosomes, transferosomes, phytosomes, microspheres, nanoparticles, and liquid crystal nanoparticles, is used to treat cancer. Lyotropic nonlamellar liquid crystalline nanoparticles (LCNs) are thought to be efficient drug delivery devices because of their unique structural characteristics. The interior nanostructure of LCNs is highly organized and thermodynamically stable, making them useful for forming a matrix for prolonged drug release. They provide us with a safer, more effective, and less hazardous substitute for current medication delivery techniques. Because LCNPs are targeted specific, harmless to normal cells, enhanced drug solubility and bioavailability, improved drug stability, and tumor-specificity, they are now being investigated for application in a variety of cancers, including lung, prostate, and breast cancer. The current study primarily addresses LNCs, including their categories, benefits and drawbacks, mode of action, structure, use, and prospects for the future. Additionally, we have included a synopsis of how LCNPs are used in cancer therapies. LNCs have the potential to be a viable method for the focused therapy of cancer and a capable substitute for the way that cancer is now treated.
Cite this article:
Umesh B. Kolap, Himmat Singh Chawara, Sunil T. Galatage. Liquid Crystal Nanoparticles: A Novel Strategy for Improved Cancer Treatment. Research Journal Pharmacy and Technology. 2025;18(11):5612-8. doi: 10.52711/0974-360X.2025.00810
Cite(Electronic):
Umesh B. Kolap, Himmat Singh Chawara, Sunil T. Galatage. Liquid Crystal Nanoparticles: A Novel Strategy for Improved Cancer Treatment. Research Journal Pharmacy and Technology. 2025;18(11):5612-8. doi: 10.52711/0974-360X.2025.00810 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-72
REFERENCES:
1. Chandraprasad MS, Dey A, Swamy MK. Introduction to cancer and treatment approaches. In Paclitaxel. 2022; (pp. 1-27). Academic Press.
2. Kumar R, Saha P, Sarkar S, Rawat N, Prakash A. A Review on Novel Drug Delivery System. IJRAR-International Journal of Research and Analytical Reviews (IJRAR). 2021; Jan; 8(1): 183-99.
3. Patel D, Pathak B. A Comparative Study on Applications of Novel Drug Delivery System for Herbal Formulations.
4. Sultana A, Zare M, Thomas V, Kumar TS, Ramakrishna S. Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Medicine in Drug Discovery. 2022 Sep 1;15:100134.
5. Sanli O, Karaca I, Isiklan N. J Appl Polym Sci. 2009; 111: 2731–40.
6. Lasic DD, Papahadjopoulos D, editors. Medical applications of liposomes. Elsevier; 1998; Jul 22.
7. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharmaceutica Sinica B. 2011; Dec 1; 1(4): 208-19.
8. Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, Kuotsu K. Niosome: a future of targeted drug delivery systems. Journal of Advanced Pharmaceutical Technology and Research. 2010; Oct 1; 1(4): 374-80.
9. Kaur D, Kumar S. Niosomes: present scenario and future aspects. Journal of Drug Delivery and Therapeutics. 2018; Sep 6; 8(5): 35-43.
10. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biological and Pharmaceutical Bulletin. 2011; Jul 1; 34(7): 945-53.
11. Biswas GR, Majee SB. Niosomes in ocular drug delivery. Eur. J. Pharm. Med. Res. 2017; 4(7): 813-9.
12. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems—an overview. Advances in Colloid and Interface Science. 2012; Nov 15; 183: 46-54.
13. Sachan R, Parashar T, Singh V, Singh G, Tyagi S, Patel C, Gupta A. Drug carrier transfersomes: A novel tool for transdermal drug delivery system. International Journal of Research and Development in Pharmacy and Life Sciences. 2013; Feb; 2(2): 309-16.
14. Kumar PR, Vijaya LA. An overview on nanobased drug delivery system. Research Journal of Pharmacy and Technology. 2020; 13(10): 4996-5003.
15. Ramandeep S, Ashutosh U, Kale MK. Effect of Liposomes as a carrier on Pharmacokinetics of Cisplatin. Research J. Pharm. and Tech. 2018; 11(11): 5073-7.
16. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery. 2008; Sep; 7(9): 771-82.
17. Singhvi G, Banerjee S, Khosa A. Lyotropic liquid crystal nanoparticles: a novel improved lipidic drug delivery system. In Organic Materials as Smart Nanocarriers for drug Delivery 2018; (pp. 471-517). William Andrew Publishing.
18. Patel D, Pathak B. A Comparative Study on Applications of Novel Drug Delivery System for Herbal Formulations.
19. Andrienko D. Introduction to liquid crystals. Journal of Molecular Liquids. 2018; Oct 1; 267: 520-41.
20. Floriano-Sanchez E, Rodriguez NC, Bandala C, Coballase-Urrutia E, Lopez-Cruz J. CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pacific Journal of Cancer Prevention. 2014; 15(8): 3805-9.
21. Gurusamy U, Shewade DG. Pharmacogenomics in India. In: Handbook of Pharmacogenomics and Stratified Medicine. Elsevier; 2014. p. 1037-59. https://doi.org/10.1016/b978-0-12-386882-4.00046-3.
22. Karami Z, Hamidi M. Cubosomes: remarkable drug delivery potential. Drug Discovery Today. 2016; May 1; 21(5): 789-801.
23. Leu JS, Teoh JJ, Ling AL, Chong J, Loo YS, Mat Azmi ID, Zahid NI, Bose RJ, Madheswaran T. Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems. Pharmaceutics. 2023; May 6; 15(5): 1421.
24. Sirisha S. A review on delivery of anti-cancer drugs by smart nanocarriers: Data obtained from past one decade. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(3): 185-90.
25. Ram DT, Debnath S, Babu MN, Nath TC, Thejeswi B. A review on solid lipid nanoparticles. Research Journal of Pharmacy and Technology. 2012; 5(11): 1359-68.
26. Chountoulesi M, Pispas S, Tseti IK, Demetzos C. Lyotropic liquid crystalline nanostructures as drug delivery systems and vaccine platforms. Pharmaceuticals. 2022; Mar 31; 15(4): 429.
27. Akbar S, Anwar A, Ayish A, Elliott JM, Squires AM. Phytantriol based smart nano-carriers for drug delivery applications. European Journal of Pharmaceutical Sciences. 2017; Apr 1; 101: 31-42.
28. Rizwan SB, Assmus D, Boehnke A, Hanley T, Boyd BJ, Rades T, Hook S. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. European Journal of Pharmaceutics and Biopharmaceutics. 2011; Sep 1; 79(1): 15-22.
29. Kumar A, Kashyap DK, Verma KK. A review on cubosome: The novel drug delivery systems. Asian Journal of Pharmacy and Technology. 2024; 14(1): 50-4.
30. Viswanathan S, Kumar NV, Srinivasan P, Prabhu S. Nanoparticle-mediated drug delivery systems. Research Journal of Engineering and Technology. 2013; 4(4): 295-9.
31. Mujariya RZ, Muzumdar A. Niosomes-An Overview. Research Journal of Pharmaceutical Dosage Forms and Technology. 2012; 4(4): 202-6.
32. Kumbhar P, Manjappa A, Shah R, Jha NK, Singh SK, Dua K, Disouza J and Patravale V. Inhalation delivery of repurposed drugs for lung cancer: Approaches, benefits and challenges. J Control Release, 2022; 341: 1–15. http://dx.doi.org/10.1016/j.jconrel.2021.11.015.
33. Kegade P, Gade A, Sawant R, Parkar S. Liposomal drug delivery in Cancer. Asian Journal of Pharmaceutical Research. 2020; 10(4): 293-8.
34. Nikam NR, Patil PR, Vakhariya RR, Magdum CS. Liposomes: A novel drug delivery system: An overview. Asian Journal of Pharmaceutical Research. 2020; 10(1): 23-8.
35. Prashar D, Sharma D. Cubosomes: a sustained drug delivery carrier. Asian Journal of Research in Pharmaceutical Science. 2011; 1(3): 59-62.
36. Unnam S, Manjappa AS, MuddanaEswara BR, Salawi A, Gunti P. Liposomal Melphalan: Approach to obtain improved plasma stability, pharmacokinetics, and in vitro and in vivo anticancer efficacy in combination with liposomal simvastatin against mouse RPMI-8226 multiple myeloma model. J Drug Deliv Sci Technol. 2022; 73(103479): 103479. http://dx.doi.org/10.1016/j.jddst.2022.103479.
37. Galatage, S. T., Trivedi, R., and Bhagwat, D. A., Oral self-emulsifying nanoemulsion systems for enhancing dissolution, bioavailability and anticancer effects of camptothecin. Journal of Drug Delivery Science and Technology. 78 (2022) 103929.
38. Sheetal M. Development and Characterization of Docetaxel Encapsulated pH-Sensitive Liposomes for Cancer Therapy. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013; 5(3): 151-60.
39. Galatage ST, Manjappa AS, Bhagwat DA, Trivedi R, Salawi A, Sabei FY, Alsalhi A. Oral self- nanoemulsifying drug delivery systems for enhancing bioavailability and anticancer potential of fosfestrol: In vitro and In vivo characterization. Eur J Pharm Biopharm. 2023; 17: S0939-6411(23)00273-4. doi: 10.1016/j.ejpb.2023.10.013.
40. Galatage, S.T., Hebalkar, A.S., Gote, R.V. Design and characterization of camptothecin gel for treatment of epidermoid carcinoma. Futur J Pharm Sci. 2020; 6; 50. https://doi.org/10.1186/s43094-020-00066-6.
41. Galatage ST, Trivedi R, Bhagwat DA. Characterization of camptothecin by analytical methods and determination of anticancer potential against prostate cancer. Future Journal of Pharmaceutical Science. 202; 7(104): 1-9. doi.org/10.1186/s 43094- 021- 00236-0.
42. Manjappa AS, Kumbhar PS, Kasabe R, Diwate SK, Disouza JI. Ameliorated in vitro anticancer efficacy of methotrexate d-α-Tocopheryl polyethylene glycol 1000 succinate ester against breast cancer cells. Futur J Pharm Sci. 2019; 5(1). http://dx.doi.org/10.1186/s43094-019-0013-x.
43. Galatage, S. T., Trivedi, R., and Bhagwat, D. A., Oral self-emulsifying nanoemulsion systems for enhancing dissolution, bioavailability and anticancer effects of camptothecin. Journal of Drug Delivery Science and Technology. 2022; 78: 103929.